|drug2805||Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Wiki||0.45|
There is one clinical trial.
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above.
Description: The efficacy of Ad5-nCoV in preventing virologically confirmed (PCR positive) COVID-19 diseaseMeasure: Incidence of COVID-19 cases Time: day 28 to 12 months post vaccination
Description: Evaluate the incidence of severe adverse events (SAE)Measure: Incidence of SAE Time: Within 12 months
Description: Evaluate the efficacy of Ad5-nCoV in preventing severe COVID-19 disease caused by SARS-CoV-2 infectionMeasure: Incidence of severe COVID-19 cases Time: Day 14 to 12 months post vaccination
Description: Incidence of solicited adverse reactions within 7 days after vaccination, in a subsetMeasure: Incidence of solicited adverse reactions Time: Day 0-7 post vaccination
Description: Incidence of unsolicited adverse events within 28 days after vaccination in a subsetMeasure: Incidence of unsolicited adverse events Time: Day 0-28 post vaccination
Description: The seroconversion rate of S-RBD IgG antibody post vaccinationMeasure: Immunogencity of S-RBD IgG antibody (ELISA method) Time: Day 28 post vaccination
Description: The seroconversion rate of neutralizing antibodyMeasure: Immunogencity of neutralizing antibody Time: Day 28 post vaccination
Description: Number of cell-mediated immune response against SARS-CoV-2Measure: Cell-mediated immune profile Time: Day 28 post vaccination
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports